Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Jim Wilson’s move to industry is anchored in global vision for ultrarare diseases

Gene therapy pioneer tells BioCentury his plans for his newcos GemmaBio and Franklin Biolabs

August 7, 2024 11:51 PM UTC

Jim Wilson and members of his team from the University of Pennsylvania are moving to industry to take on the challenges of gene therapy development at a time when many companies and investors are shying away from the therapeutic modality. In an exclusive conversation with BioCentury, Wilson described how he plans to use his newly launched start-up GemmaBio as a vehicle to create a sustainable model for ultrarare disease gene therapies by capitalizing on efficiencies gained from a platform model. The goal is global development, commercialization and access.

Last week, Wilson announced his planned departure from Penn and the formation of two new companies — Gemma Biotherapeutics Inc. and Franklin Biolabs Inc. Gemma is a therapeutics play that will advance a pipeline of gene therapies from Penn, while Franklin Biolabs will house translational infrastructure from Penn’s Gene Therapy Program (GTP) and serve as a genetic medicine CRO...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article